Meta‐analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. BJS 2017; 104: 814-822.
Published: 18th May 2017
Authors: A. Acharya, S. R. Markar, M. H. Sodergren, G. Malietzis, A. Darzi, T. Athanasiou et al.
Periampullary cancers are uncommon malignancies, often amenable to surgery. Several studies have suggested a role for adjuvant chemotherapy and chemoradiotherapy in improving survival of patients with periampullary cancers, with variable results. The aim of this meta‐analysis was to determine the survival benefit of adjuvant therapy for periampullary cancers.
A systematic review was undertaken of literature published between 1 January 2000 and 31 December 2015 to elicit and analyse the pooled overall survival associated with the use of either adjuvant chemotherapy or chemoradiotherapy
A total of 704 titles were screened, of which 93 full‐text articles were retrieved. Fourteen full‐text articles were included in the study, six of which were
This systematic review found no associated survival benefit for adjuvant chemotherapy or chemoradiotherapy in the treatment of periampullary cancer.Read more
You may also be interested in
Randomized clinical trial
Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection. BJS 2017; 104: 1462-1469.
Authors: S. B. Ellebæk, C. W. Fristrup, C. Hovendal, N. Qvist, L. Bundgaard, S. Salomon et al.
Notes: No additional benefit
Randomized clinical trial
Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. BJS 2017; 104: 1443-1450.
Authors: C. Palanivelu, P. Senthilnathan, S. C. Sabnis, N. S. Babu, S. Srivatsan Gurumurthy, N. Anand Vijai et al.
Notes: Shorter stay
Authors: K. J. Roberts
Authors: B. Le Roy, M. Gelli, G. Pittau, M.‐A. Allard, B. Pereira, B. Serji et al.
Notes: Option to increase resectability
Authors: A. J. Klompenhouwer, M. E. E. Bröker, M. G. J. Thomeer, M. P. Gaspersz, R. A. de Man, J. N. M. IJzermans et al.
Notes: Wait and see policy justified
Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. BJS 2017; 104: 1568-1577.
Authors: L. G. M. van der Geest, V. E. P. P. Lemmens, I. H. J. T. de Hingh, C. J. H. M. van Laarhoven, T. L. Bollen, C. Y. Nio et al.
Notes: Negative impacts
Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. BJS 2017; 104: 1539-1548.
Authors: R. Ravikumar, C. Sabin, M. Abu Hilal, A. Al‐Hilli, S. Aroori, G. Bond‐Smith et al.
Notes: No difference between type of reconstruction
Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. BJS 2017; 104: 1558-1567.
Authors: D. Kleive, M. A. Sahakyan, A. E. Berstad, C. S. Verbeke, I. P. Gladhaug, B. Edwin et al.
Notes: Severe complications, more reoperations
Authors: R. Green, S. C. Charman, T. Palser
Notes: Variation in compliance related to outcomes
Pancreatoduodenectomy with portal vein resection for distal cholangiocarcinoma. BJS 2017; 104: 1549-1557.
Authors: T. Maeta, T. Ebata, E. Hayashi, T. Kawahara, S. Mizuno, N. Matsumoto et al.
Notes: Poor survival despite portal vein resection
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma.
Authors: A. Cucchetti, V. Mazzaferro, A. D. Pinna, C. Sposito, R. Golfieri, C. Serra et al.
Notes: Resection is better